vs
ENANTA PHARMACEUTICALS INC（ENTA）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
ENANTA PHARMACEUTICALS INC的季度营收约是RIVERVIEW BANCORP INC的1.3倍（$18.6M vs $14.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -64.1%，领先73.9%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs 9.8%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-11.8M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs 4.5%）
Enanta制药是一家临床阶段生物技术企业，专注于研发针对乙型肝炎病毒、呼吸道合胞病毒、新冠病毒等传染性疾病的创新抗病毒疗法，与全球制药伙伴合作推进小分子候选药物管线，满足未被覆盖的临床需求。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
ENTA vs RVSB — 直观对比
营收规模更大
ENTA
是对方的1.3倍
$14.0M
营收增速更快
RVSB
高出0.6%
9.8%
净利率更高
RVSB
高出73.9%
-64.1%
自由现金流更多
RVSB
多$11.1M
$-11.8M
两年增速更快
RVSB
近两年复合增速
4.5%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $18.6M | $14.0M |
| 净利润 | $-11.9M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -60.5% | 12.4% |
| 净利率 | -64.1% | 9.8% |
| 营收同比 | 9.8% | 10.4% |
| 净利润同比 | 46.4% | 11.8% |
| 每股收益（稀释后） | $-0.42 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENTARVSB
| Q4 25 | $18.6M | $14.0M | ||
| Q3 25 | $15.1M | $13.6M | ||
| Q2 25 | $18.3M | $13.3M | ||
| Q1 25 | $14.9M | $12.9M | ||
| Q4 24 | $17.0M | $12.7M | ||
| Q3 24 | $14.6M | $12.8M | ||
| Q2 24 | $18.0M | $12.2M | ||
| Q1 24 | $17.1M | $9.0M |
净利润ENTARVSB
| Q4 25 | $-11.9M | $1.4M | ||
| Q3 25 | $-18.7M | $1.1M | ||
| Q2 25 | $-18.3M | $1.2M | ||
| Q1 25 | $-22.6M | $1.1M | ||
| Q4 24 | $-22.3M | $1.2M | ||
| Q3 24 | $-28.8M | $1.6M | ||
| Q2 24 | $-22.7M | $966.0K | ||
| Q1 24 | $-31.2M | $-3.0M |
营业利润率ENTARVSB
| Q4 25 | -60.5% | 12.4% | ||
| Q3 25 | -121.6% | 10.2% | ||
| Q2 25 | -103.2% | 11.7% | ||
| Q1 25 | -164.3% | 11.3% | ||
| Q4 24 | -138.8% | 12.4% | ||
| Q3 24 | -204.4% | 15.5% | ||
| Q2 24 | -134.6% | 10.0% | ||
| Q1 24 | -192.1% | -47.5% |
净利率ENTARVSB
| Q4 25 | -64.1% | 9.8% | ||
| Q3 25 | -123.6% | 8.1% | ||
| Q2 25 | -99.7% | 9.2% | ||
| Q1 25 | -151.7% | 8.9% | ||
| Q4 24 | -131.4% | 9.7% | ||
| Q3 24 | -197.3% | 12.2% | ||
| Q2 24 | -126.1% | 7.9% | ||
| Q1 24 | -182.7% | -34.7% |
每股收益（稀释后）ENTARVSB
| Q4 25 | $-0.42 | $0.07 | ||
| Q3 25 | $-0.88 | $0.05 | ||
| Q2 25 | $-0.85 | $0.06 | ||
| Q1 25 | $-1.06 | $0.05 | ||
| Q4 24 | $-1.05 | $0.06 | ||
| Q3 24 | $-1.36 | $0.07 | ||
| Q2 24 | $-1.07 | $0.05 | ||
| Q1 24 | $-1.47 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $37.4M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $126.6M | $164.2M |
| 总资产 | $329.5M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ENTARVSB
| Q4 25 | $37.4M | $28.6M | ||
| Q3 25 | $32.3M | $32.8M | ||
| Q2 25 | $44.8M | $34.2M | ||
| Q1 25 | $60.2M | $29.4M | ||
| Q4 24 | $84.3M | $25.3M | ||
| Q3 24 | $37.2M | $31.0M | ||
| Q2 24 | $35.8M | $27.8M | ||
| Q1 24 | $63.5M | $23.6M |
股东权益ENTARVSB
| Q4 25 | $126.6M | $164.2M | ||
| Q3 25 | $64.7M | $163.5M | ||
| Q2 25 | $79.3M | $162.0M | ||
| Q1 25 | $93.5M | $160.0M | ||
| Q4 24 | $111.8M | $158.3M | ||
| Q3 24 | $128.8M | $160.8M | ||
| Q2 24 | $148.9M | $155.9M | ||
| Q1 24 | $166.1M | $155.6M |
总资产ENTARVSB
| Q4 25 | $329.5M | $1.5B | ||
| Q3 25 | $280.7M | $1.5B | ||
| Q2 25 | $301.0M | $1.5B | ||
| Q1 25 | $323.0M | $1.5B | ||
| Q4 24 | $348.6M | $1.5B | ||
| Q3 24 | $376.7M | $1.5B | ||
| Q2 24 | $398.8M | $1.5B | ||
| Q1 24 | $413.6M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.7M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-11.8M | $-736.0K |
| 自由现金流率自由现金流/营收 | -63.6% | -5.2% |
| 资本支出强度资本支出/营收 | 0.8% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-18.5M | $20.4M |
8季度趋势，按日历期对齐
经营现金流ENTARVSB
| Q4 25 | $-11.7M | $-506.0K | ||
| Q3 25 | $-6.5M | $16.8M | ||
| Q2 25 | $17.5M | $-697.0K | ||
| Q1 25 | $-13.5M | $8.3M | ||
| Q4 24 | $-16.8M | $2.2M | ||
| Q3 24 | $-10.4M | $764.0K | ||
| Q2 24 | $-14.8M | $5.4M | ||
| Q1 24 | $-28.6M | $12.8M |
自由现金流ENTARVSB
| Q4 25 | $-11.8M | $-736.0K | ||
| Q3 25 | $-7.9M | $16.4M | ||
| Q2 25 | $17.4M | $-773.0K | ||
| Q1 25 | $-16.0M | $5.6M | ||
| Q4 24 | $-25.5M | $1.9M | ||
| Q3 24 | $-19.4M | $-1.4M | ||
| Q2 24 | $-21.3M | $5.3M | ||
| Q1 24 | $-30.3M | $7.1M |
自由现金流率ENTARVSB
| Q4 25 | -63.6% | -5.2% | ||
| Q3 25 | -52.5% | 120.1% | ||
| Q2 25 | 94.7% | -5.8% | ||
| Q1 25 | -107.4% | 43.1% | ||
| Q4 24 | -150.6% | 15.0% | ||
| Q3 24 | -132.5% | -11.3% | ||
| Q2 24 | -118.6% | 43.7% | ||
| Q1 24 | -177.5% | 79.0% |
资本支出强度ENTARVSB
| Q4 25 | 0.8% | 1.6% | ||
| Q3 25 | 9.6% | 2.9% | ||
| Q2 25 | 0.8% | 0.6% | ||
| Q1 25 | 17.0% | 21.0% | ||
| Q4 24 | 51.6% | 2.4% | ||
| Q3 24 | 61.3% | 17.3% | ||
| Q2 24 | 36.4% | 0.9% | ||
| Q1 24 | 9.8% | 62.0% |
现金转化率ENTARVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
